17:07 , May 11, 2018 |  BC Week In Review  |  Financial News

InflaRx raises $51M follow-on

Inflammatory diseases company InflaRx N.V. (NASDAQ:IFRX) raised $51 million on May 3 through the sale of 1.5 million shares at $34 in a follow-on underwritten by J.P. Morgan, Leerink, BMO Capital Markets and SunTrust Robinson...
02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
20:34 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial...
21:23 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

InflaRx reports Phase IIa data of mAb against C5a for rare inflammatory skin disease

In September, InflaRx N.V. (NASDAQ:IFRX) reported data from a Phase IIa trial in 12 patients with moderate to severe hidradenitis suppurativa showing that IV IFX-1 (CaCP29) led to response rates of 75% at week 8...
20:43 , Nov 10, 2017 |  BC Week In Review  |  Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Nov. 8 through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the...
19:12 , Nov 8, 2017 |  BC Extra  |  Financial News

InflaRx prices $100M IPO

InflaRx N.V. (NASDAQ:IFRX) raised $100 million on Wednesday through the sale of 6.7 million shares at $15 in an IPO underwritten by JPMorgan, Leerink and BMO Capital Markets. The share price is at the midpoint...
21:14 , Oct 13, 2017 |  BC Week In Review  |  Financial News

InflaRx raises $55M in series D

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included...
18:04 , Oct 13, 2017 |  BC Extra  |  Financial News

InflaRx raises $55M in series D round

InflaRx GmbH (Jena, Germany) raised $55 million in a series D round from Bain Capital Life Sciences, Cormorant Asset Management, RA Capital and undisclosed funds managed by a U.S. firm. InflaRx said the round included...
23:53 , Sep 21, 2017 |  BC Extra  |  Clinical News

Akari gains on Phase III PNH plans for C5 inhibitor

Akari Therapeutics plc (NASDAQ:AKTX) gained $3.15 (56%) to $8.74 on Thursday after the company announced plans to start Phase III testing in 1Q18 of lead candidate Coversin to treat paroxysmal nocturnal hemoglobinuria. The announcement appears to...
23:20 , Jul 11, 2017 |  BioCentury  |  Emerging Company Profile

Complementary ALS play

Alsonex Pty. Ltd. is targeting a central component of the complement cascade to quell neuroinflammation in amyotrophic lateral sclerosis without excessively dampening the immune system. That mechanism could slow disease progression and improve life expectancy...